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Abstract
Background: The catechol-O-methyltransferase (COMT) enzyme has a key function in the degradation of catecholamines
and a functional polymorphism is val158met. The val/val genotype results in a three to fourfold higher enzymatic activity
compared with the met/met genotype, with the val/met genotype exhibiting intermediate activity. Since pain syndromes as
well as anxiety and depression are associated to low and high COMT activity respectively and these conditions are all
associated with irritable bowel syndrome (IBS) we wanted for the first time to explore the relationship between the
polymorphism and IBS.
Methodology/Principal Findings: 867 subjects (445 women) representative of the general population and 70 consecutively
sampled patients with IBS (61 women) were genotyped for the val158met polymorphism and the IBS patients filled out the
Hospital-Anxiety-and-Depression-Scale (HADS) questionnaire, and an IBS symptom diary.
Results: There was a significantly higher occurrence of the val/val genotype in patients compared with controls (30% vs
20%; Chi
2 (1) 3.98; p=0.046) and a trend toward a lower occurrence of the val/met genotype in IBS patients compared with
controls (39% vs 49%; Chi
2 (1) 2.89; p=0.089). Within the IBS patients the val/val carriers exhibited significantly increased
bowel frequency (2.6 vs 1.8 stools per day; Chi
2 (1) 5.3; p=0.03) and a smaller proportion of stools with incomplete
defecation (41% vs 68%; Chi
2 (1) 4.3; p=0.04) compared with the rest (val/met+met/met carriers). The val/val carriers also
showed a trend for a smaller proportion of hard stools (0% vs 15%; Chi
2 (1) 3.2; p=0.08) and a higher frequency of
postprandial defecation (26% vs 21%; Chi
2 (1) 3.0; p=0.08).
Conclusions/Significance: In this study we found an association between the val/val genotype of the val158met COMT
gene and IBS as well as to specific IBS related bowel pattern in IBS patients.
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Introduction
Irritable bowel syndrome (IBS) is a functional gastrointestinal
disorder characterized by abdominal discomfort in combination
with altered bowel habits in the absence of organic disease. The
prevalence of IBS in the western population is estimated to 5–11%
[1]. The causes of IBS are not known. Abnormalities in gut
immunology, inflammation [2] and brain-gut communications
have been proposed [3]. Visceral hypersensitivity is demonstrated
in 50–80% of patients with IBS and the origin of this phenomenon
is probably based on both peripheral and central nervous system
(CNS) mechanisms [1,4]. Abnormalities in CNS interpretation of
visceral afferent signals and dysfunction in the endogenous pain
modulation system may contribute to visceral hypersensitivity
[3,5]. Patients with IBS also have high rates of anxiety and
depression and patients suffering from anxiety and depression
have more IBS-like symptoms [6–8]. The pathophysiological links
between anxiety and depression and the gut is not fully understood
but it has been proposed that changes in the endogenous pain
modulation system, the autonomic nervous system (ANS) and the
hypothalamus-pituitary-adrenal (HPA) axis may each play a role
[3].
Catechol-o-methyltransferase (COMT) has a key function in the
degradation of catecholamines (dopamine, noradrenaline and
adrenaline). A common polymorphism in the COMT gene
(located at chromosome 22q11.2) is val158met (rs4680), which
causes a valine (val) substitution to methionine (met) and is
responsible for a variation in function of the enzyme. The val/val
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enzyme compared with the met/met genotype, and the val/met
genotype shows intermediate activity [9–11]. A low COMT
activity also results in higher levels of dopamine and chronic
activation of dopaminergic neurons which results in lower
neuronal content of enkephalin and a decreased activity level of
the endogenous pain inhibitory system [9]. The opposite is true
with a high COMT activity. Experimental studies in humans
(hypertonic saline infusion into the masseter muscle) showed that
individuals with the met/met genotype (low COMT activity)
exhibited diminished regional m-opioid receptors activity, higher
sensory and affective ratings of pain in response to painful stimuli
compared to the val/val individuals [9]. Low COMT activity has
also been associated to chronic pain conditions such as facial pain
[12,13], fibromyalgia [14] and with non-migrainous headache
[15], whereas the val/val genotype has been associated to anxiety/
depression [16].
On the background that both chronic pain syndromes [17] and
anxiety/depression [6–8] are associated to low and high COMT
activity respectively and both are associated with IBS/IBS-like
symptoms we wanted for the first time to explore the relationship
between the val158met COMT polymorphism and IBS. The
hypothesized association between IBS and the COMT polymor-
phism would based on the aforementioned relationships predict
that val/val (high COMT activity) and met/met (low COMT
activity) genotypes would be the high risk genotypes. These two
genotypes would be associated with increased risk of IBS possibly
via separate mechanistic routes whereas the val/met (intermediate
COMT activity) genotype would be predicted to be the low risk,
protective genotype.
Methods
IBS patient and control samples
Seventy consecutive patients with IBS (87% women), all
referred from primary care to the gastroenterological out-patient
department at the University Hospital of Northern Sweden and all
fulfilling the ROME III criteria [18]. The subjects representative
of the general population (n=867, 51% women) were part of a
large multiple outcome study, the Betula study, investigating broad
domains of cognition, psychiatric and somatic health [8,19,20].
Within the Betula study, the participants were recruited by
random selection through a population register. The only
exclusion criteria for enrollment into the Betula study were
dementia, mental retardation, serious visual or auditory handi-
caps, not having Swedish as a mother tongue or any other feature
that would have compromised the ability to comply with the study.
None of these conditions or features considered to potentially
compromise the ability to comply with the study were exhibited by
any of the IBS patients. The representativity of the Betula sample
towards the general population of the region of Umea ˚, Sweden has
been demonstrated to be excellent [20]. All subjects within the
present study were 50 years or younger, were from the same
geographical region of Umea ˚, Northern Sweden, were Caucasian,
had Swedish as their mother tongue and gave their informed
(written or verbal) consent to participate. All research in Sweden is
required by law to be approved by at least one of six regional
committees for human ethics. This study was approved by the
ethics committee in Umea ˚ (Regionala Etikpro ¨vningsna ¨mden i
Umea ˚). All participants received verbal and written information of
the study. All subjects in the Betula project (control group) gave
written consent. The IBS patients received written information
and gave verbal consent. The IBS subjects were patients at our
department, and to avoid to interact the patient-doctor relation-
ship we did not demand a written consent (this was approved by
the ethical committee).
Questionnaires
The patients with IBS prospectively filled in a two week
validated symptom diary [21]. The Hospital Anxiety and
Depression Scale (HADS), a highly sensitive instrument to screen
for symptoms of anxiety and depression among patients with
somatic disease, was used to detect these symptoms in the patients
with IBS [22,23]. HADS consists of seven items each for anxiety
and depression, each using a 4-point Likert scale (0–3 points). 77%
of the IBS patients completed the symptom diary and 97% the
HADS questionnaire.
Medical records
After informed consent from the patients with IBS, records of
primary care were searched to define consulters for chronic pain.
Consulters for chronic pain were defined as pain more than 6
months, both explained and unexplained pain was included. Ten
areas of somatic pain were defined: head, neck, thoracal and
lumbar spine, shoulder, arm, hand, hip, knee and foot.
Val158met COMT
Genotyping was performed by pyrosequencing on a PSQ HS96
pyrosequencer ((Pyrosequencing AB, Uppsala, Sweden). Biotiny-
lated polymerase chain reaction (PCR) products were obtained by
performing a 35 cycles PCR reaction (conditions: 30 seconds (sec)
at 95 degrees Celsius (uC); 30 sec 68uC ; 30 sec 72uC) using
primers: ACCCAGCGGATGGTGGATTT (COMT-F biotiny-
lated) CCTTTTTCCAGGTCTGACAAC (COMT-R). Next, the
obtained biotinylated PCR products were immobilized onto
streptavidin-coated sepharose beads (Amersham Biosciences,
Sweden). Biotinylated single strand DNA was obtained by
incubating the immobilized PCR products in 0.5 mol/L NaOH,
followed by two sequential washes in 10 mmol/L Tris-acetate,
pH 7.6. Primer annealing for SNP analysis (GCA-
CACCTTGTCCTTCA) was performed by incubation at 80uC
for 2 minutes and then at room temperature for 5 minutes [24].
Statistics
We used PASW statistics 17.0.2 (SPSS Inc., Chicago, IL, USA).
Median values were used for all ordinal scales, including
proportions. Non-parametric Kruskal-Wallis tests were used for
comparisons between groups concerning ordinal data. Student t-
test was used for continuous data. Chi
2 test was used for cross table
analyses. Logistic regression was used to adjust for age and gender.
A p-value less than 0.05 was regarded as statistically significant
and a p-value between 0.05 and 0.15 as borderline significant. The
results were not corrected for multiple testing. Statistical power
calculations (http://www.dssresearch.com/toolkit/spcalc/power.
asp) were performed for key analyses.
Results
Comparisons concerning the val158met COMT
polymorphism genotype frequencies between the IBS
patients and the sample representative of the general
population
The control subjects were older (mean age 43.5 years vs 31.1
years; p,0.001) and had more male subjects (49% vs 13%, Chi
2
(1) 33.1; p,0.001) compared to the patients with IBS. There was a
higher occurrence of the val/val genotype in patients compared
with controls (30% vs 20%; Chi
2 (1) 3.98; p=0.046) and a trend
Val158Met COMT and IBS
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compared with controls (39% vs 49%; Chi
2 (1) 2.89; p=0.089).
Comparing the women only we found no significant differences in
the genotype frequencies between controls and patients. None of
the 9 male IBS patients had the met/met genotype (Table 1).
Using logistic regression adjusting for gender and age we found a
borderline significant association between IBS and the val/val
genotype (adjusted OR: 2.02; CI: 0.95–4.29) and a lower
occurrence of the val/met genotype in patients with IBS (adjusted
OR: 0.57; CI: 0.28–1.13).
Gastrointestinal symptoms in patients with IBS in relation
to val158met COMT polymorphism
Within the IBS patient sample, the val/val genotype, based on a
two week validated symptom diary, was significantly associated
with increased bowel frequency (2.6 vs 1.8 stools per day; Chi
2 (1)
5.3; p=0.03) and with a smaller proportion of stools with
incomplete defecation (41% vs 68%; Chi
2 (1) 4.3; p=0.04)
compared with the rest (val/met+met/met carriers). There was
also a trend towards a smaller proportion of hard stools (0% vs
15%; Chi
2 (1) 3.2; p=0.08) and a higher frequency of postprandial
defecation (26% vs 21%; Chi
2 (1) 3.0; p=0.08) among the val/val
carriers compared with the rest (Table 2).
Anxiety, Depression and Health seeking behaviour in
relation to the val158met COMT polymorphism
There was no significant difference in HADS scores between
different genotypes among the patients with IBS. The val/met
carriers tended to have less HADS-depression score compared to
the other genotypes (2.5 vs 5.0; Chi
2 (1) 2.6; p=0.11). There was
no difference in health seeking behavior (visits per year in primary
care) between the different genotypes except a trend for more visits
per year in primary care for subjects with met/met genotype
within the IBS patient sample (2.0 vs 1.4; Chi
2 (1) 2.7; p=0.10)
(Table 3).
Chronic pain in relation to the val158met COMT
polymorphism
Consulting behavior for chronic somatic symptoms was
analyzed in the patients with IBS in relation to the val158met
polymorphism. We found no significant differences in chronic pain
(more than two areas of chronic somatic pain), chronic headache,
chronic neck pain and chronic lumbago between subjects carrying
the three different COMT genotypes. There was a trend towards
more consulting for pain in the met/met genotype compared to
the other genotypes almost reaching statistical significance for neck
pain (36% vs 19%; Chi
2 (1) 2.5; p=0.12) (Table 3).
Statistical Power analyses
Power calculations were performed for key analyses within the
study. The statistical power using a one-tail test and an alpha error
of 5% concerning the frequency difference of the val/val genotype
between IBS patients and controls was 62%. We calculated that
the preferable number of IBS patients should have been 127
patients to reach 80% statistical power. The statistical power
employing a one-tail test and an alpha error of 5% concerning the
frequency difference in the number of stools between IBS patients
carrying the val/val genotype compared to the IBS patients
carrying the val/met and the met/met genotypes was 72%, with
an additional 10 more subjects needed to reach 80% statistical
power.
Discussion
COMT is a key regulator in the degradation of catecholamines
and individual differences in the activity of the enzyme have been
shown to influence the interpretation of pain and negative
environmental stimuli [9,25]. This study is to our knowledge the
first study to explore the relationship between COMT polymor-
phism and IBS. We found a significantly higher occurrence of the
val/val genotype and a trend towards a lower occurrence of the
val/met genotype among the patients with IBS compared to the
control population from the same geographical region (Umea ˚,
Sweden). These differences were based on comparisons between
the total patient and control samples but did not remain significant
if only female IBS patients and female controls were included in
the analysis. The study was slightly underpowered and since the
control sample was representative of the general population the
sample is expected to contain subjects suffering from IBS but the
diagnostic status with respect to IBS within the control sample was
not available. These facts might explain the loss of significance
when the women were analyzed separately.
However, using logistic regression, adjusting for age and gender
there was a borderline significant association between the val/val
genotype and IBS and a trend towards a protective effect of the
heterozygous val/met genotype. Patients seeking help for IBS are
predominately women and there are also some differences in
symptom presentation between men and women, where abdom-
inal pain and constipation-related symptoms are more common in
women whereas men more likely report diarrhea-related symp-
toms [26]. The patients with the val/val genotype in our study
(both men and women) reported prospectively more bowel
movements, fewer harder stools and more stools after meals than
the patients with the other genotypes indicating an association
between the val/val genotype and the diarrhea-dominant IBS-
subtype.
Both population studies and studies on patient with IBS show a
significant correlation between symptom of anxiety and diarrhea
[8,19]. The val/val genotype has been associated with anxiety
(Caucasian women) [16], to faster and better recognition of
negative facial expression [25], and a reduction in the ability to
experience rewards [27]. Anxiety and confrontation with fearful
faces have also been shown to enhance perception of signals from
the gut [28–30] which raises the question whether the val/val
genotype predisposes towards increased perception of abnormal
gut physiological events. In the present study the patients with IBS
showed no differences in HADS-anxiety score between the
Table 1. The distribution of the val158met COMT
polymorphism in patients with IBS compared to a sample
representative of the general population.
met/met val/met val/val
IBS women+men (n=70) 31% 39% 30%*
Controls women+men (n=867) 31% 49% 20%
IBS women (n=61) 36% 38% 26%
Controls women (n=445) 32% 48% 20%
IBS men (n=9) 0% 44% 56%
Controls men (n=422) 30% 51% 19%
There was a higher occurrence of the val/val genotype in patients compared
with controls (30% vs 20%; Chi
2 (1) 3.98; p=0.046) and a trend toward a lower
occurrence of the val/met genotype in IBS patients compared with controls
(39% vs 49%; Chi
2 (1) 2.89; p=0.089).
*Statistically significant; p,0.05.
doi:10.1371/journal.pone.0018035.t001
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tinal tract of the ‘‘val/val’’ individuals are more sensitive to
activation of the stress system resulting in increased bowel
movements and/or lower threshold for defecation signals. In
addition, other mechanisms than stress related pathways could be
involved, and the influence of an increased degradation of
catecholamines (high COMT activity) on the gastrointestinal tract
is probably complex and may involve both central and peripheral
actions.
A recent Japanese study on patients with functional dyspepsia
also showed in consistency with our data a lower frequency of the
met allele among dyspeptic patients but the difference was not
significant [31].
The met/met genotype with a decreased COMT activity has
been associated with a decreased activity level of the endogenous
pain inhibitory system and increased chronic somatic pain. For
example a low COMT activity has been associated with chronic
facial pain [12,13], fibromyalgia [14] and women with non-
migrainous headache [15].
In the present study we found no significant differences in
consulting behaviour for chronic pain, but a trend for more
chronic pain, especially neck pain in the IBS patient carrying the
met/met allele. However within the present study the met/met
genotype carriers did not differ in prospectively reporting
abdominal pain, in comparison with the other genotype carriers.
In a large Norwegian study, investigating musculoskeletal
symptoms in a sample representative of the general population
they found no association between different musculoskeletal
symptoms including chronic chest/abdominal pain and the
different val158met COMT genotypes [32]. Neither did they find
Table 2. Characteristics of the patients with IBS in relation to val158met COMT polymorphism based on the symptom diary.
met/met
carriers (n=19)
val/met
carriers (n=18)
val/val carriers
(n=17)
Chi
2 (2); All three
genotype carriers vs
each other p-value
Chi
2 (1); val/val vs the
other carriers; p-value
Mean pain hours per day 2.6 2.7 3.5 ns ns
Mean bloating hours per day 3.9 3.5 3.0 ns ns
Mean stools per day 1.9 1.5 2.6 6.5; p=0.04* 5.3; p=0.03*
Percentage of days with no stools 7% 16% 0% 10.1; p=0.006* 6.4; p=0.02*
Percentage of loose stools 27% 48% 47% ns ns
Percentage of hard stools 16% 13% 0% ns 3.2; p=0.08
Percentage of stools with urgency 52% 38% 42% ns ns
Percentage of stools with straining 45% 52% 42% ns ns
Percentage of stools with
incomplete emptying
80% 55% 41% 4.4; p=0.12 4.3; p=0.04*
Percentage of meals followed by
defecation (Gastro-colon reflex)
23% 18% 26% 5.5; p=0.07 3.0; p=0.08
54 IBS subjects (48 women) completed the symptom diary. The val/val genotype was significantly associated with multiple measures clustering towards IBS-diarrhea-
like symptoms compared with the rest (val/met+met/met carriers). Statistics: Kruskal-Wallis (all three genotypes compared against each other in column 5, and val/val
carriers compared with the other carriers grouped together in column 6).
*Statistically significant: p,0.05. Borderline statistically significant: p values between 0.05–0.15. ns=non-significant.
doi:10.1371/journal.pone.0018035.t002
Table 3. Anxiety, depression, health seeking behaviour and consulting for chronic pain in relation to the val158met COMT
polymorphism among patients with IBS.
met/met carriers (n=22) val/met carriers (n=27) val/val carriers (n=21) statistics
Mean age (years) 32.2 29.7 31.9 ns
Mean BMI 24.6 25.2 23.0 ns
HADS-Anxiety 9.5 7.5 8.0 ns
HADS-Depression 5.0 2.5 5.0 val/met vs others: chi
2 (1) 2.6; p=0.11
Visits per year in primary care 2.0 1.4 1.7 met/met vs others: chi
2 (1) 2.7; p=0.10
Two or more parts of the body
with chronic somatic pain
45% 27% 38% ns
Chronic headache 23% 18% 19% ns
Chronic neck pain 36% 19% 19% met/met vs others: chi
2 (1) 2.5; p=0.12
Chronic lumbago 36% 22% 29% ns
There was no significant difference in age, BMI, HADS scores, health seeking behavior and consulting for chronic pain between different genotypes among 70 patients
(61 women) with IBS. However, the val/met carriers tended to have less HADS-depression score compared to the other genotypes and the met/met genotype tended
have more visits per year in primary care and more chronic neck pain. BMI=Body mass index. HADS=Hospital anxiety depression scale. ns=Non-significant.
*Statistically significant: p,0.05. Borderline statistically significant: p values between 0.05–0.15. ns=non-significant.
doi:10.1371/journal.pone.0018035.t003
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COMT polymorphism [33]. However, these conflicting data does
not exclude that the met/met genotype predisposes to pain in
subgroups of patients, for example in individuals with severe
multifocal pain. Lastly, there is diversity in the pathophysiological
mechanisms of visceral and somatic nociceptive pain [4], so
COMT activity may influence the perception of musculoskeletal
and abdominal pain differently.
To conclude, in this study we aimed to study the relationship
between COMT function and IBS, both of which have been
demonstrated to be associated with pain and anxiety/depression.
We found a significant association between the val/val genotype
and IBS and a trend towards a protective role of the heterozygous
val/met genotype for IBS. The val/val genotype was associated
with diarrhea-like symptomatology in patients with IBS. We
believe that this study justify further research of the val158met
COMT polymorphism in a larger samples of IBS patients. It
would be warranted and interesting to investigate these genotypes
in different subgroups of IBS patients, for example in IBS patients
with and without other unexplained pain syndromes, and in IBS
patients with different bowel patterns.
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